AUS
NZ
UK
CA
USA
IND
Source: PalSand, Shutterstock
Summary
- The British government denied false EU claims over vaccine nationalism concerns.
- Pandemic seems to have proved the worth of prominent vaccine stocks – AZN, MRNA, PFE and BNTX.
A diplomatic row broke out after the European Union (EU) officials claimed that Britain had imposed a ban on export of all Covid vaccines produced in the country. But a news report in BBC quoted UK’s Foreign Secretary Dominic Raab who had termed the allegations as false. The UK foreign office has reportedly summoned Nicole Mannion, EU's deputy ambassador to the UK, to discuss the issue further.
Copyright © 2021 Kalkine Media Pty Ltd.
The European leaders are under stress over slow distribution of the vaccine in the EU. Meanwhile in Britain, almost one-third of the population (22.5 million people) has been administered with the first jab. The nation is likely to have a big vaccine surplus after ordering 400 million doses of the shots and would donate the left over to less developed nations, according to government sources.
The EU was reportedly facing production problems with AstraZeneca plc (LON:AZN), Moderna Inc (NASDAQ:MRNA), and Pfizer-BioNTech vaccines.
Let us take a closer look at these vaccine companies and their recent stock trends.
Also Read: EU to Ask the US to Export AstraZeneca/Oxford Vaccine: Report
AstraZeneca plc
Struggling with Spain’s sluggish vaccination rollout, the national health authorities have urged the Spanish government to widen the categories of people who are eligible to take the AstraZeneca shot by including more elderly patients (above 55 years old) in the list. However, critics are quick to point out that the nation is facing shipment delays. The company shares (LON: AZN) were up 0.84 per cent at GBX 7186 at 2.07 PM on Wednesday, 10 March.
The stock was giving a one-year return of 2.67 per cent with a market cap of £93.6 billion at 2.07 PM on Wednesday. The share price is down nearly 3 per cent since the beginning of the year.
Also Read: Why Moderna, Pfizer Et Al Are Poised for Strong Gains in FY 2021
Moderna Inc
The American pharma company (NASDAQ:MRNA) is trying to produce a Covid-19 vaccine to target more than one strain of the virus. This will strengthen its immunisation campaign as the pathogen evolves. The company researchers are putting effort to get ahead of the Brazilian, South African and the British variants.
In the past, the company stock (NASDAQ:MRNA) was firmly rooted under US $35 per share during the late 2019. The company was plagued by losses and its mRNA technology had not been tested on humans.
Today, the company boasts of successful commercial products with analysts expecting the company to further grow its sales and profits going forward. Share price of MRNA stock was up 3.23 per cent at 9.37 AM on 10 March, reaching US $134.10.
Pfizer and BioNTech
The Pfizer-BioNTech Covid-19 vaccine has been able to neutralise a Covid-19 variant identified in Brazil. The BioNTech stock (NASDAQ:BNTX) jumped 4.19 per cent to US $100.67 at 9.52 AM on Wednesday, 10 March. The BNTX stock had gone public at US $15 a share in late 2019. It later hit an all-time high of US $131 in December 2020.
Pfizer stock (NYSE:PFE) also marginally rose by 0.19 per cent to US $34.62 on the New York Stock Exchange at 9.54 AM on 10 March.
